Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation
The blockade of immune checkpoints, such as programmed death receptor 1 (PD-1) and programmed death ligand 1 protein (PD-L1), is a promising therapeutic approach in cancer immunotherapy. Nivolumab, a humanized IgG4 antibody targeting PD-1, was approved by the US Food and Drug Administration for seve...
Main Authors: | Wenping Liu, Haoyu Jin, Ting Chen, Gangping Zhang, Shengsheng Lai, Guangjian Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmolb.2020.574759/full |
Similar Items
-
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
by: Bernhard Roither, et al.
Published: (2020-12-01) -
Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
by: Joanna Bialek, et al.
Published: (2022-12-01) -
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01) -
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
by: Bingxin Zheng, et al.
Published: (2018-02-01) -
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)